FDA-cleared profile

OsteoSight™ Hip (v1)

Naitive Technologies Ltd · X-ray/Radiography · FDA-cleared (510(k))

Authorized purpose: Opportunistically analyzes standard AP hip or pelvis radiographs in patients aged 50 years and older and issues a report when the estimated femoral-neck BMD is below a preset threshold to prompt clinical bone-health assessment; absence of a report does not rule out low BMD.

Clinical role
AI pipeline estimates femoral-neck BMD; when below a pre-specified threshold, it delivers a report to the interpreting physician flagging possible low BMD to prompt a clinical bone-health assessment; it should not be used to rule out low BMD.
Images and patients
X-ray/Radiography · MSK
Key limitation
Keep in mind: A missing or above-threshold report does not rule out low BMD; clinicians should follow recommended screening and assessment regardless of the report, and the FDA packet does not establish current commercial hosting or support terms.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Opportunistically analyzes standard AP hip or pelvis radiographs in patients aged 50 years and older and issues a report when the estimated femoral-neck BMD is below a preset threshold to prompt clinical bone-health assessment; absence of a report does not rule out low BMD.
  • Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: MSK Input: Standard anteroposterior (AP) radiographs of the hip or pelvis from patients aged 50 years and older, received as DICOM images with associated metadata from clinical imaging systems via a host integration platform.
  • Who uses it?Intended users: Radiologists and/or physician interpreters
  • What does the software produce?Output: OsteoSight applies an AI-enabled algorithm pipeline to estimate bone mineral density (BMD) at the femoral neck. The algorithm presents a binary output to indicate whether the patient likely has low BMD at the femoral neck. If an estimated BMD is below the pre-specified threshold, OsteoSight generates a report (Results Report) indicating that the patient is at risk of having low BMD, which is delivered to the interpreting physician via the host integration platform. If the estimated BMD is above or equal to the pre-specified threshold, no report is generated.
  • What is its most important limitation?Key limitation: A missing or above-threshold report does not rule out low BMD; clinicians should follow recommended screening and assessment regardless of the report, and the FDA packet does not establish current commercial hosting or support terms.

Clinical takeaway. Clinical role: Opportunistically analyzes standard AP hip or pelvis radiographs in patients aged 50 years and older and issues a report when the estimated femoral-neck BMD is below a preset threshold to prompt clinical bone-health assessment; absence of a report does not rule out low BMD.

Evidence takeaway. Evidence from the reviewed source record: Study type: Stand-Alone Performance. Cases: 3082. Sites: 6. Reported sensitivity: 37% (95% CI: 34.9%, 39.1%). Reported specificity: 95.1% (95% CI: 93.6%, 96.3%)

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Opportunistically analyzes standard AP hip or pelvis radiographs in patients aged 50 years and older and issues a report when the estimated femoral-neck BMD is below a preset threshold to prompt clinical bone-health assessment; absence of a report does not rule out low BMD.
  • Exact FDA submission
  • Checked 2026-09-06

Exact clinical-use normalization from the FDA packet; this text is also the locked corrections value.

Workflow role
AI pipeline estimates femoral-neck BMD; when below a pre-specified threshold, it delivers a report to the interpreting physician flagging possible low BMD to prompt a clinical bone-health assessment; it should not be used to rule out low BMD.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "OsteoSight applies an AI-enabled algorithm pipeline to estimate bone mineral density (BMD) at the femoral neck. If an estimated BMD is below the pre-specified threshold, OsteoSight generates a report indicating that the patient is at risk of having low BMD." … "This report is delivered to the interpreting physician via the host integration platform.". Read from the exact FDA decision document on 2026-11-14.

Required input
Standard anteroposterior (AP) radiographs of the hip or pelvis from patients aged 50 years and older, received as DICOM images with associated metadata from clinical imaging systems via a host integration platform.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "processes standard anteroposterior (AP) radiographs of the hip or pelvis in patients aged 50 years and older." … "The device operates via integration with a host integration platform that facilitates the secure transfer of DICOM images and associated metadata from clinical imaging systems.". Read from the exact FDA decision document on 2026-11-14.

Output and clinician action
OsteoSight applies an AI-enabled algorithm pipeline to estimate bone mineral density (BMD) at the femoral neck. The algorithm presents a binary output to indicate whether the patient likely has low BMD at the femoral neck. If an estimated BMD is below the pre-specified threshold, OsteoSight generates a report (Results Report) indicating that the patient is at risk of having low BMD, which is delivered to the interpreting physician via the host integration platform. If the estimated BMD is above or equal to the pre-specified threshold, no report is generated.
  • Exact FDA submission
  • Checked 2026-09-01

Clinical output reported in the exact-submission ACR model card.

Care setting
Adult
  • Exact FDA submission
  • Checked 2026-09-01

Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.

Intended users
Radiologists and/or physician interpreters
  • Exact FDA submission
  • Checked 2026-09-01

Intended-user text reported in the exact-submission ACR model card.

Limitations
A missing or above-threshold report does not rule out low BMD; clinicians should follow recommended screening and assessment regardless of the report, and the FDA packet does not establish current commercial hosting or support terms.
  • Exact FDA submission
  • Checked 2026-09-06

Exact-product limitations and clinician-review boundary from the FDA packet.

Evidence summary
Study type: Stand-Alone Performance. Cases: 3082. Sites: 6. Reported sensitivity: 37% (95% CI: 34.9%, 39.1%). Reported specificity: 95.1% (95% CI: 93.6%, 96.3%)
  • Exact FDA submission
  • Checked 2026-09-01

Structured study metadata from the exact-submission ACR model card; this is not an independent evidence synthesis.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Study type: Stand-Alone Performance. Cases: 3082. Sites: 6. Reported sensitivity: 37% (95% CI: 34.9%, 39.1%). Reported specificity: 95.1% (95% CI: 93.6%, 96.3%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Structured study metadata from the exact-submission ACR model card; this is not an independent evidence synthesis.

Reported sensitivity
37% (95% CI: 34.9%, 39.1%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
95.1% (95% CI: 93.6%, 96.3%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Sensitivity

0.37 proportion

  • EndpointSensitivity for femoral-neck BMD below the preset threshold
  • PopulationIntended-use validation of standard AP hip or pelvis radiographs from adults aged 50 years and older across 6 sites
  • Tested versionOsteoSight Hip (v1); FDA submission K251408

OsteoSight™ Hip (v1) regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K251408
  • Samplen=3082
  • Sites6
  • IndependenceIndependence not established

K251408

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Opportunistic assessment of osteoporosis using hip and pelvic X-rays with OsteoSight: validation of an AI-based tool in a US population

  • DesignPeer-reviewed diagnostic validation study
  • PopulationUS population with hip or pelvic X-rays compared with DXA; robustness and reproducibility were evaluated across demographic groups and scanner hardware
  • Scopeproduct family
  • Tested versionOsteoSight product family; exact commercial release not reported
  • IndependenceSponsor or vendor study

PMID:40263144 · PMCID:PMC12122585 · DOI:10.1007/s00198-025-07487-0

Authors include Naitive employees/shareholders; treat as vendor-sponsored family evidence, not independent exact-release performance. The abstract reports preprocessing exclusions for wrong body parts, metalwork, and unacceptable femur positioning.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Standard anteroposterior (AP) radiographs of the hip or pelvis from patients aged 50 years and older, received as DICOM images with associated metadata from clinical imaging systems via a host integration platform.

    Scope: Exact FDA submission. Packet wording: "processes standard anteroposterior (AP) radiographs of the hip or pelvis in patients aged 50 years and older." … "The device operates via integration with a host integration platform that facilitates the secure transfer of DICOM images and associated metadata from clinical imaging systems.". Read from the exact FDA decision document on 2026-11-14.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-11-14 · FDA 510(k) decision material K251408: OsteoSight Hip

  2. Routing

    Source context, not route validation: The exact-submission ACR model card explicitly references DICOM and PACS in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.

    Scope: Exact FDA submission. Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-01 · OsteoSight™ Hip (v1) model card (K251408)

  3. AI processing

    Source context, not route validation: The exact FDA package describes OsteoSight as able to be installed in the cloud via a host integration platform, which may be within the existing secured network of a clinical site. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "be installed in the cloud, via a host integration" … "platform, which may be within the existing". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA 510(k) decision material K251408: OsteoSight Hip

  4. Returned objects

    Source context, not route validation: OsteoSight applies an AI-enabled algorithm pipeline to estimate bone mineral density (BMD) at the femoral neck. The algorithm presents a binary output to indicate whether the patient likely has low BMD at the femoral neck. If an estimated BMD is below the pre-specified threshold, OsteoSight generates a report (Results Report) indicating that the patient is at risk of having low BMD, which is delivered to the interpreting physician via the host integration platform. If the estimated BMD is above or equal to the pre-specified threshold, no report is generated.

    Scope: Exact FDA submission. Clinical output reported in the exact-submission ACR model card.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-01 · OsteoSight™ Hip (v1) model card (K251408)

  5. Viewer/worklist/report

    Unresolved route: OsteoSight applies an AI-enabled algorithm pipeline to estimate bone mineral density (BMD) at the femoral neck. The algorithm presents a binary output to indicate whether the patient likely has low BMD at the femoral neck. If an estimated BMD is below the pre-specified threshold, OsteoSight generates a report (Results Report) indicating that the patient is at risk of having low BMD, which is delivered to the interpreting physician via the host integration platform. If the estimated BMD is above or equal to the pre-specified threshold, no report is generated.

    Scope: Exact FDA submission. Clinical output reported in the exact-submission ACR model card.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-01 · OsteoSight™ Hip (v1) model card (K251408)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes OsteoSight as able to be installed in the cloud via a host integration platform, which may be within the existing secured network of a clinical site. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "be installed in the cloud, via a host integration" … "platform, which may be within the existing". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The exact-submission ACR model card explicitly references DICOM and PACS in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-09-01

Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

Family pre-operative workflow

Naitive describes OsteoSight as background X-ray analysis intended to provide an evidence-backed flag for orthopedic surgeons before surgery.

product family · checked 2026-09-06

Exact site workflow, hosting, and support terms require confirmation.

Family input-quality handling

The peer-reviewed family study reports exclusion of unsuitable cases such as wrong body parts, metalwork, or unacceptable femur positioning before analysis.

product family · checked 2026-09-06

Product-family study; it does not establish exact K251408 commercial release behavior.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K251408
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
X-ray/Radiography
  • Public source
  • Exact FDA submission
  • Checked 2026-09-06

Imaging modality reported in the exact-submission ACR AI Central model card.

Anatomy
MSK
  • Public source
  • Exact FDA submission
  • Checked 2026-09-06

Anatomy normalized from explicit exact-submission ACR model-card wording.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-09-02
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
28Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Stored exact-submission candidate metadata had zero PubMed and ClinicalTrials.gov identifiers; this metadata screening is not a full paper or registry-record review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, peer reviewed publication, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-06 - Exact FDA submission

    Official non-FDA product sources were reviewed for buyer and workflow context, but no exact-submission amount, currency, unit, term, or implementation fee was displayed. A vendor quote remains required.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Naitive Technologies reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. No result was a vendor or payer page naming this product with coding or payment; any results were general billing guidance. This records what was found, not that none exists.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-08-13 - Exact FDA submission

    FDA authorization does not establish the current commercial security posture. Request data-flow diagrams, hosting and retention details, access controls, audit logging, attestations, and incident-response documentation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-08-13 - Exact FDA submission

    Training, onboarding, competency, and support commitments are commercial implementation details that require current vendor documentation.

  • Monitoring: Not verified - checked 2026-08-13 - Exact FDA submission

    Local acceptance testing, production monitoring, drift review, update control, and incident escalation require a current vendor and site-specific governance plan.

9 sources - 3 history items

Source ledger

  1. K251408 FDA decision source

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, purpose, modality, anatomy

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. OsteoSight™ Hip (v1) model card (K251408)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: purpose, modality, intendedUsers, careSetting, output, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. FDA 510(k) decision material K251408: OsteoSight Hip

    U.S. Food and Drug Administration - Accessed 2026-09-06

    Scope: identity, clinical, evidence, implementation, deployment

  8. OsteoSight

    Naitive Technologies - Accessed 2026-09-06

    Scope: buyer_workflow, clinical, implementation

  9. Opportunistic assessment of osteoporosis using hip and pelvic X-rays with OsteoSight: validation of an AI-based tool in a US population

    Osteoporosis International / PMC - Accessed 2026-09-06

    Scope: family_evidence, clinical, implementation

Research history

  1. K251408 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K242171

TechCare Trauma

Milvue

Authorized purpose: Aids clinicians and radiologists reviewing 2D X-ray radiographs by detecting, localizing, and characterizing fractures across the FDA-listed appendicular, hip/pelvis, clavicle, and thorax/rib examinations, and by detecting elbow joint effusion on lateral elbow or forearm views in children/adolescents and adults; results are not standalone clinical decisions.

Modality
X-ray/Radiography
Anatomy
MSK
Decision
2025-01-17
FDA-cleared K240845

Rayvolve

AZmed SAS

Authorized purpose: Assists radiologists and emergency physicians in detecting fractures on DICOM musculoskeletal radiographs for adults and children aged 2 years or older, limited to the FDA-listed anatomic areas and standard views (ankle, clavicle, elbow, forearm, hip, humerus, knee, pelvis, shoulder, tibia/fibula, wrist, hand, and foot); it is an aided-diagnosis device and does not operate autonomously.

Modality
X-ray/Radiography
Anatomy
MSK
Decision
2024-07-17
FDA-cleared K193417

FractureDetect (FX)

Imagen Technologies, Inc.

Authorized purpose: Assists clinicians in detecting fractures during review of adult musculoskeletal radiographs.

Modality
X-ray/Radiography
Anatomy
MSK
Decision
2020-07-30
FDA-cleared K192109

KOALA

IB Lab GmbH

Authorized purpose: The Knee OsteoArthritis Labeling Assistant (KOALA) software provides metric measurements of the joint space width and indicators for presence or absence of radiographic features of osteoarthritis (OA) on PA/AP knee X-ray images.

Modality
X-ray/Radiography
Anatomy
MSK
Decision
2019-11-05

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history